A Phase 3 interventional study of MC2-01 cream and Cal/BDP combination in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by MC2 Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 7th largest by enrollment, is one of 5 that started in 2017, is one of 17 in phase 3, and was the 33rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 794 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
MC2 Therapeutics is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
MC2 Therapeutics has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
The MC2-01 Cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines. In this trial, the MC2-01 cream will be compared to a marketed product CAL/BDP combination and vehicle. The purpose of the trial is to compare the clinical efficacy, safety, and convenience of this cream to the marketed product. The trial will include a 8-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
Drug: MC2-01 cream
Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
Drug: Cal/BDP combination
One application daily for 8 weeks.
Drug: Cream vehicle
Drug pages: Calcipotriene · Betamethasone dipropionate
MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
Vehicle Cream
Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8
Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening. The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.
Time frame: Baseline and 8 weeks
Percentage Change in mPASI Score
The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement. The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe. The mPASI score is calculated from the individual scores by use of the following equation: Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8. The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100
Time frame: Baseline and 8 weeks
Psoriasis Treatment Convenience Scale
Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10. How easy was the treatment to apply to the skin? "Very difficult" is 1 and "Very easy" is 10 How greasy was the treatment when applying it to the skin? "Very greasy" is 1 and "Not greasy" is 10 How moisturised did your skin feel after applying the treatment? "Not moisturized" is 1 and "Very moisturized" is 10 How greasy did your skin feel after applying the treatment? "Very greasy" is 1 and "Not greasy" is 10 How much did treating your skin disrupt your daily routine? "Very disturbing" is 1 and "Not disturbing" is 10
Time frame: 8 weeks
First Subject First Visit: 03-Oct-2017. Last Subject Last Visit: 08-Jun-2018.
| Milestone | MC2-01 Cream | CAL/BDP Combination | Vehicle |
|---|---|---|---|
| Started | 342 | 337 | 115 |
| Completed | 320 | 309 | 94 |
| Not completed | 22 | 28 | 21 |
Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening. The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.
| Count of participants | MC2-01 Cream | CAL/BDP Combination | Vehicle |
|---|---|---|---|
| Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8 | 121 | 67 | 4 |
The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement. The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe. The mPASI score is calculated from the individual scores by use of the following equation: Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8. The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100
| Percentage of change | MC2-01 Cream | CAL/BDP Combination | Vehicle |
|---|---|---|---|
| Percentage Change in mPASI Score | 64.8 ± 28.7 | 52.3 ± 33.3 | 25.7 ± 35.3 |
Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10. How easy was the treatment to apply to the skin? "Very difficult" is 1 and "Very easy" is 10 How greasy was the treatment when applying it to the skin? "Very greasy" is 1 and "Not greasy" is 10 How moisturised did your skin feel after applying the treatment? "Not moisturized" is 1 and "Very moisturized" is 10 How greasy did your skin feel after applying the treatment? "Very greasy" is 1 and "Not greasy" is 10 How much did treating your skin disrupt your daily routine? "Very disturbing" is 1 and "Not disturbing" is 10
| score on a scale | MC2-01 Cream | CAL/BDP Combination | Vehicle |
|---|---|---|---|
| Psoriasis Treatment Convenience Scale | 41.6 ± 6.6 | 37.8 ± 7.6 | 37.2 ± 7.1 |
Collected over AEs were collected/assessed during the screening period (up to 4 weeks) and during the 8 weeks treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MC2-01 Cream | 1/342 (0.3%) | 9/342 (2.6%) | 0/342 (0%) |
| CAL/BDP Combination | 0/337 (0%) | 11/337 (3.3%) | 0/337 (0%) |
| Vehicle | 1/115 (0.9%) | 5/115 (4.3%) | 0/115 (0%) |
| Event | MC2-01 Cream | CAL/BDP Combination | Vehicle |
|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 1/342 | 0/337 | 1/115 |
| Application site cellulitisSkin and subcutaneous tissue disorders | 0/342 | 1/337 | 1/115 |
| CholecystitisGastrointestinal disorders | 0/342 | 0/337 | 1/115 |
| Ischaemic strokeCardiac disorders | 0/342 | 0/337 | 1/115 |
| DeathCardiac disorders | 0/342 | 0/337 | 1/115 |
| AbscessSkin and subcutaneous tissue disorders | 1/342 | 1/337 | 0/115 |
| Angina PectorisCardiac disorders | 1/342 | 1/337 | 0/115 |
| PneumoniaInfections and infestations | 1/342 | 1/337 | 0/115 |
| DehydrationMetabolism and nutrition disorders | 0/342 | 1/337 | 0/115 |
| PyrexiaInfections and infestations | 0/342 | 1/337 | 0/115 |
| Age, Continuous(Years) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| Mean | 52.0 ± 14.4 | 52.6 ± 13.7 | 50.4 ± 14.3 | 52.0 ± 14.1 |
| Sex: Female, Male(Participants) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| Female | 139 | 116 | 44 | 299 |
| Male | 203 | 221 | 71 | 495 |
| Race/Ethnicity, Customized(Participants) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| Race — White | 290 | 299 | 102 | 691 |
| Race — Black or African American | 34 | 20 | 11 | 65 |
| Race — Asian | 10 | 10 | 1 | 21 |
| Race — American Indian or Alaska Native | 3 | 3 | 1 | 7 |
| Race — Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 3 |
| Race — Mutiple | 2 | 3 | 0 | 5 |
| Race — Other | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| United States | 342 | 337 | 115 | 794 |
| Baseline PGA(Participants) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| Mild psoriasis | 68 | 57 | 20 | 145 |
| Moderate psoriasis | 274 | 280 | 95 | 649 |
| Baseline mPASI(Calculated score) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| Mean | 7.3 ± 3.9 | 7.7 ± 4.1 | 7.1 ± 4.1 | 7.4 ± 4.0 |
| Baseline BSA(Percentage) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| Mean | 7.3 ± 6.0 | 8.4 ± 7.0 | 7.5 ± 6.1 | 7.8 ± 6.5 |
| Fitzpatrick Skin Type(Participants) | MC2-01 Cream | CAL/BDP Combination | Vehicle | Total |
|---|---|---|---|---|
| I | 21 | 21 | 9 | 51 |
| II | 86 | 88 | 30 | 204 |
| III | 104 | 112 | 37 | 253 |
| IV | 87 | 73 | 23 | 183 |
| V | 30 | 28 | 9 | 67 |
| VI | 14 | 15 | 7 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Jun 2018, 8 months.
Results were first posted in Oct 2019, 1 year 4 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate
MC2 Therapeutics